Anju Software Inc, a portfolio company of Providence Equity Partners, has acquired the assets of Sylogent, a provider of software and business services for the pharmaceutical industry. No financial terms were disclosed. Madison Park Group provided financial advice to Anju on the transaction.
NEW YORK–(BUSINESS WIRE)–Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired the assets of Sylogent.
“Sylogent has cloud based state of the art software solutions that enhance current Anju solutions in the Medical Affairs and Clinical Trials space,” said Kurien Jacob, CEO of Anju Software. “PUBSTRAT is the only cloud-based solution for publication planning, which is integrated with industry critical scientific journal and medical conference profiles. VTCR is a Clinical Disclosure solution that streamlines compliance with global disclosure and transparency regulation requirements. In addition, Sylogent has SAM for document approvals workflow automation and SYQUENCE, a data and information lifecycle management platform, which is currently being introduced to the industry,” Mr. Jacob continued. Jacob also added that the acquisition of Sylogent is consistent with Anju’s strategy of continuing to enhance its product offering through acquisitions and internal development.
“Anju will bring financial strength and scale, along with the additional resources that are critical to support our customers and essential to accelerate growth,” said Jack Yeager, CEO and owner of Sylogent. Yeager will continue to work with Anju to enhance and grow the current and new Sylogent product offerings with Anju customers and with new customers in Life Sciences.
“We are pleased with the execution of Anju’s growth strategy with the acquisition of Sylogent. After having established a leading position in Medical Affairs with the acquisitions of OBA and OpenQ, we believe Sylogent will accelerate Anju’s growth in the Medical Affairs and Clinical Trial segment,” said Gopi Vaddi, Managing Director of Providence Strategic Growth.
Snell & Wilmer acted as legal counsel to Anju and Madison Park Group acted as financial advisors to Anju on the transaction.
About Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions. Anju was founded by a group of operating and investment professionals with deep software domain expertise and a proven track record of building software platforms through strategic acquisitions and organic growth. In 2016, Anju acquired Online Business Applications (OBA), which is the market leader in providing medical information solutions to the pharmaceutical and CRO industries, acquired OpenQ in April 2017, a leader in Key Opinion Leader (KOL) management and acquired ClinPlus in July 2017 which has complete Clinical Trial Management Software.
Anju Software is a portfolio company of Providence Strategic Growth, the growth equity affiliate of Providence Equity Partners, a global private equity firm with more than $54 billion in capital under management.
Sylogent delivers software and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market. The company is uniquely positioned to operate within core business units, and across the enterprise, to ensure timely completion of critical information, maximize compliance goals and reduce risk management liability.
About Providence Equity
Providence is a premier global private equity firm with more than $54 billion in capital under management. Providence pioneered a sector-focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm’s inception in 1989, Providence has invested in more than 160 companies and is the leading equity investment firm focused on the media, communications, education and information industries. Providence is headquartered in Providence, RI, and also has offices in New York and London. For more information, please visit www.provequity.com.